Tg Therapeutics (TGTX) Cash from Operations (2011 - 2026)

Tg Therapeutics' Cash from Operations history runs 16 years deep, the most recent figure standing at 17894000.0 for Q1 2026.

• In Q1 2026, Cash from Operations rose 37.68% year-over-year to 17894000.0; the TTM figure through Mar 2026 stood at 13951000.0 (up 77.14% YoY), while the FY2025 annual figure was 24772000.0, up 38.86% from the prior year.
• Cash from Operations was 17894000.0 for Q1 2026 at Tg Therapeutics, down from 19660000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 83704000.0 in Q3 2023 to a low of 68689000.0 in Q1 2022.
• Historically, Cash from Operations has averaged 17103882.35 across 5 years, with a median of 23153000.0 in 2025.
• The sharpest annual moves came in 2023 and 2025: Cash from Operations soared 342.66% in 2023, then plunged 249.88% in 2025.
• A 5-year view of Cash from Operations shows it stood at 23870000.0 in 2022, then surged by 44.66% to 13210000.0 in 2023, then slumped by 94.1% to 25641000.0 in 2024, then jumped by 176.67% to 19660000.0 in 2025, then slumped by 191.02% to 17894000.0 in 2026.
• The last three Cash from Operations figures came in at 17894000.0 (Q1 2026), 19660000.0 (Q4 2025), and 23153000.0 (Q3 2025), per Business Quant data.